AstraZeneca's Beyfortus Included for RSV Immunization
Trusted by teams at
Description
AstraZeneca's co-manufactured Beyfortus monoclonal antibody is recommended for use in the 2025–2026 RSV immunization schedule for pediatric patients. Providers are directed to utilize any available authorized RSV-mAb product.
Contract Details
Vendor
ASTRAZENECA
Agency
Prince William County Public Schools, VA
Contract Type
SUPPLIES
Document Date
January 1, 2025
Contract Term
2025-2026 RSV season
Renewal Date
2026-03-31
Renewal Info
Coverage updated annually based on RSV season recommendations.
More from ASTRAZENECA
More from Prince William County Public Schools
Prince William County Public Schools Minutes School Board Meeting 2026-06-03
Prince William County Public Schools Minutes School Board Meeting 2026-06-03
Prince William County Public Schools Minutes School Board Meeting 2026-06-03
Prince William County Public Schools Minutes School Board Meeting 2026-06-03
Prince William County Public Schools Minutes School Board Meeting 2026-06-03
Get alerts on contract renewals, new awards, and vendor activity.
See live SLED buying signals, source docs, decision-makers, contract context, and the next step into your CRM or pipeline.